On May 16, 2019, ESSA Pharma Inc. (“ESSA”) (TSX-V: EPI; NASDAQ: EPIX) and Realm Therapeutics plc (“Realm”) (NASDAQ: RLM) announced that they entered into a definitive agreement whereby ESSA would acquire all of the issued and outstanding shares of Realm in an all-share transaction. The acquisition, which remains subject to the approval of Realm’s shareholders, is intended to be implemented by means of a United Kingdom court-sanctioned scheme of arrangement, and is expected to be completed by the middle of 2019. Fasken acted as Canadian counsel to Realm, with a team comprised of Jay Lefton (Corporate), Myroslav Chwaluk (Corporate), Ryan Schnier (Corporate), Armand Benitah (Intellectual Property), Christopher Steeves (Tax), Timothy Squire (Regulatory), Karen Sargeant (Labour and Employment) and Ross Gascho (Benefits).
Client Work
Essa Pharma signs agreement to purchase Realm Therapeutics
Fasken
Reading Time
1 minute read
Overview
Overview
Team
Team
- Myroslav Chwaluk, Partner, Toronto, ON, +1 416 868 3413, mchwaluk@fasken.com
- Armand M. Benitah, Partner | Patent Agent | Trademark Agent, Toronto, ON, +1 416 868 3470, abenitah@fasken.com
- Christopher Steeves, Partner | Leader, Tax Law, Toronto, ON, +1 416 868 3401, csteeves@fasken.com
- Timothy M. Squire, Partner | CO-LEADER, LIFE SCIENCES, Toronto, ON, +1 416 868 3462, tsquire@fasken.com
- Karen M. Sargeant, Partner | Managing Partner, Ontario, Toronto, ON, +1 416 868 3475, ksargeant@fasken.com
- Ross A. Gascho, Partner | Leader, Pensions and Benefits, Toronto, ON, +1 416 865 5447, rgascho@fasken.com
